samedan logo
 
 
spacer
home > ict > autumn 2017 > problematic patterns
PUBLICATIONS
International Clinical Trials

Problematic Patterns

Pneumonia, an inflammatory condition of the lung, primarily affects the alveoli, which fill with fluid and pus. This manifests in a variety of symptoms and limits oxygen intake. The causes include bacteria, viruses or fungi (1). Pneumonia classification involves healthcare-associated (otherwise called hospital-acquired) or communityacquired (CAP); when not acquired in a hospital or other medical institution. Symptoms manifest in cough (with or without sputum), fever, pleuritic chest pain and dyspnea. If untreated, pneumonia can result in bacteraemia, septic shock, lung abscesses, pleural effusion, empyema and pleurisy and respiratory or renal failure (2).

Pneumonia remains a major cause of illness and death, affecting mostly young children and the elderly. Pneumonia is the world’s leading cause of death among children under five and accounts for 15% of all deaths of children at this age (3). According to the WHO, 5% of overall mortality was caused in 2015 by lower respiratory tract infections, including pneumonia (4).

Misdiagnosis

Physicians must differentiate pneumonia from upper respiratory tract infections and other conditions (eg congestive heart failure) that share similar clinical features. Pulmonary embolism (PE) is known as ‘the great masquerader’; it presents a diagnostic dilemma and is most often mistaken for pneumonia. Dyspnea is the most common symptom of PE, and tachypnea is the most frequent sign. Patients with severe pneumonia may be very short of breath (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Daniella Bajzath, PharmD, Safety Officer at PSI CRO AG, is a graduate of Pharmaceutical Faculty, Semmelweis University, Hungary. Before joining PSI in 2016, she had worked for four years in public pharmacies in Hungary and Germany. She has experience in preparing and handing out prescription and OTC drugs and in advising patients on medical subjects in several indications.

Maxim Belotserkovskiy MD, PhD, MBA, holds the position of Head of Medical Affairs at PSI CRO AG. He has board certifications in internal medicine, rheumatology, anesthesiology, intensive care and hemodialysis. Maxim is also a certified Associate Professor of pathological physiology. He has more than 25 years of experience in clinical research as an investigator and research professional. Maxim is also the author/co-author of more than 150 publications.

Maxim Kosov MD, PhD, is a director of medical monitoring and consulting at PSI CRO, US. He is a board-certified physician in paediatrics, anaesthesiology and intensive care. Maxim is a member of American Society Clinical Oncology. He has more than 12 years of experience in clinical research industry and has experience across a board range of indications. He is also the author/co-author of more than 40 publications.

John Riefler MD, MS, is a director of medical monitoring and consulting at PSI CRO, US. His MS is in microbiology, and his clinical training is in internal medicine and infectious diseases. John is a fellow of the Infectious Disease Society of America and the American Heart Association. He has 29 years’ experience in clinical development in Big Pharma and CROs. John is also the author/co-author of 22 publications.
spacer
Daniella Bajzath
spacer
spacer
spacer
Maxim Belotserkovskiy
spacer
spacer
spacer
Maxim Kosov
spacer
spacer
spacer
John Riefler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

Vaccine Manufacturing

23-25 April 2018, RAI, Amsterdam

Changing the shape of vaccine development, manufacturing and delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement